



Virtual event

**Technology and process advancements
in cell and gene therapy development.**

| Date | Time | Track | Presentation Title | Speaker |
|--------|------------------|-------|--|---|
| 20-Mar | 10:00 - 10:30 AM | | Semi-automated, closed processing of mesenchymal stromal cells | Dr. Alan Lam, PhD Senior Scientist, Bioprocessing Technology Institute A*STAR Dr. Qu Yinghua, PhD Field Application Scientist, Cell & Gene Therapy, SEATW Thermo Fisher Scientific |
| 20-Mar | 10:35 - 11:15 AM | | Advancing process efficiency for the end-to-end manufacturing of T cell immunotherapies | Dr. Paula Lam, PhD Chief Scientific Officer, BioCell Innovations, Singapore Dr. Sylvie Shen, PhD Field Application Scientist, Cell & Gene Therapy, Australasia Thermo Fisher Scientific |
| 20-Mar | 11:20 - 11:45 AM | | The experience of development and verification of analytical platforms for cellular and gene therapy (CGT) products in EMO Biomedicine | Shing-Mou Lee CEO & Lab Head, EMO Biomedicine Corp. |
| 20-Mar | 11:50 - 12:15 PM | | Safety first: A comprehensive look at cell and gene therapy testing | Karolina Setyowati, Ph.D. Sr Product Specialist, APJ, Thermo Fisher Scientific |
| 20-Mar | 12:20 - 12:40 PM | | Regulatory considerations in raw material selection for cell and gene therapy manufacturing | Bingrong Chen Manager, Regulatory Affairs Thermo Fisher Scientific |
| 20-Mar | 12:45 - 01:15 PM | | Panel discussion | Dr. Sylvie Shen, PhD Field Application Scientist, Cell & Gene Therapy, Australasia Thermo Fisher Scientific Shing-Mou Lee CEO & Lab Head, EMO Biomedicine Corp. Bingrong Chen Manager, Regulatory Affairs Thermo Fisher Scientific |